Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2380189 Target Snapshot

Protein mono-ADP-ribosyltransferase PARP11 · SINGLE PROTEIN · Homo sapiens

67Compounds
26Assays
2Approved Drugs
81.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9NR21. Use UniProt Q9NR21 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9NR21 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Protein mono-ADP-ribosyltransferase PARP11 as ChEMBL target CHEMBL2380189, mapped to UniProt Q9NR21. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Protein mono-ADP-ribosyltransferase PARP11
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2380189
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9NR21
Protein mono-ADP-ribosyltransferase PARP11
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Protein mono-ADP-ribosyltransferase PARP11 is the right protein anchor across sources, using UniProt Q9NR21 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProtein mono-ADP-ribosyltransferase PARP11
UniProt AccessionQ9NR21
Component TypeProtein
Sequence Length338 aa

Protein mono-ADP-ribosyltransferase PARP11

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Protein mono-ADP-ribosyltransferase PARP11, mapped to UniProt Q9NR21. Sequence length is 338 aa.

Mapped IDQ9NR21
Review nameProtein mono-ADP-ribosyltransferase PARP11
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase III
1
Phase I
Assay Mix

Activity Type Distribution

IC5079.0
KD2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5191676 7.85 IC50 14.0 Preclinical
CHEMBL5199558 7.17 IC50 67.0 Preclinical
CHEMBL5207717 7.0 IC50 99.0 Preclinical
CHEMBL3137320 6.85 IC50 140.0 Approved
CHEMBL5187963 6.7 IC50 200.0 Preclinical
CHEMBL5404785 6.62 IC50 240.0 Preclinical
CHEMBL5431108 6.33 IC50 467.74 Preclinical
CHEMBL5186007 6.26 IC50 550.0 Preclinical
CHEMBL4580007 5.93 IC50 1174.9 Preclinical
CHEMBL125200 5.68 IC50 2100.0 Preclinical
Distribution

pChEMBL Value Distribution

16
5.0
12
5.5
3
6.0
4
6.5
2
7.0
3
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TALAZOPARIB
CHEMBL3137320
Approved 2018
Assay Landscape

Assay Landscape

26
Total Assays
41
Tested Compounds
1
Assay Types
Binding — 26 assays, 41 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 14 7 6.2
cell-based format 8 5 6.6
assay format 4 29 5.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine